Australija - engleski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nutrien ag solutions limited - boric acid; zinc oxide - topical cream, ointment, paste, gel, lotion - boric acid mineral-boron-acid active 15.0 g/kg; zinc oxide mineral-zinc active 30.0 g/kg - dermatological preps. - cattle | cow (teat/udder) | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | heife - cracking & chapping of teat | cut or wound disinfection | udder teat cracking/chapping

Australija - engleski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ecolab pty ltd - non-ionic detergents; phosphoric acid - liquid concentrate - non-ionic detergents emulsifiers & surfactants-noni active 30.0 g/l; phosphoric acid mineral-phosphorus-acid active 1152.0 g/l - dairy cleanser - milking equipment | milking machine - milkstone removal | milk fat | milk protein | mineral deposits

Australija - engleski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ecolab pty ltd - chlorine present as sodium dichloroisocyanurate; sodium hydroxide - soluble powder - chlorine present as sodium dichloroisocyanurate mineral-chlorine active 22.0 g/kg; sodium hydroxide mineral-sodium-base active 780.0 g/kg - dairy cleanser - milking equipment | milking machine - residue, dirt in milking equipment

Australija - engleski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ecolab pty limited - chlorhexidine gluconate; cetrimide; glycerol - topical cream, ointment, paste, gel, lotion - chlorhexidine gluconate guanidine active 1.0 g/kg; cetrimide ammonium-quaternary active 5.0 g/kg; glycerol solvent other 30.0 g/kg - dermatological preps. - dairy cattle | bovine | breeders | calves | dairy cow | growers | lactating cow | milking cow - anti-infective or antiseptic | cracking & chapping of teat | mastitis | bacterial infections | conjunctivitis | eye infections | eye-washes | keratoconjunctivitis | ocular infections | subclinical mastitis | udder teat cracking/chapping

Australija - engleski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dasco proprietary limited - available iodine; phosphoric acid - aqueous concentrate - available iodine mineral active 20.0 g/l; phosphoric acid mineral-phosphorus-acid active 120.0 g/l - dairy cleanser - dairy equipment stainless steel | dairy plant stainless steel | building - bacteria | milkstone removal | milk fat | milk protein | mineral deposits

Australija - engleski - Department of Health (Therapeutic Goods Administration)

genesis airway innovations pty ltd - 45036 - airway, laryngeal, single-use - nasal laryngeal mask device used in anesthesia and in emergency medicine for airway management.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

scott airway management - 42424 - airway, oropharyngeal, single use - the airway is used to maintain an unobstructed oral-pharyngeal airway during general anesthesia or in unconscious patients, mostly in pre-hospital emergency care. oropharyngeal airways may allow for air exchange or suction to occur with a tube or catheter.(gmdn 42424 airway, oropharyngeal, single use).

Australija - engleski - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fluticasone propionate, quantity: 250 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. evocair is not indicated for the initiation of bronchodilator therapy in copd.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fluticasone propionate, quantity: 125 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. evocair is not indicated for the initiation of bronchodilator therapy in copd.

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

csl behring llc - .alpha.1-proteinase inhibitor human (unii: f43i396ois) (.alpha.1-proteinase inhibitor human - unii:f43i396ois) - .alpha.1-proteinase inhibitor human 1000 mg in 20 ml - zemaira is an alpha1 -proteinase inhibitor (a1 -pi) indicated for chronic augmentation and maintenance therapy in adults with a1 -pi deficiency and clinical evidence of emphysema. zemaira increases antigenic and functional (anti-neutrophil elastase capacity [anec]) serum levels and lung epithelial lining fluid (elf) levels of a1 -pi. clinical data demonstrating the long-term effects of chronic augmentation therapy of individuals with zemaira are not available. the effect of augmentation therapy with zemaira or any a1 -pi product on pulmonary exacerbations and on the progression of emphysema in a1 -pi deficiency has not been demonstrated in randomized, controlled clinical studies. zemaira is not indicated as therapy for lung disease patients in whom severe a1 -pi deficiency has not been established. - zemaira is contraindicated in patients with a history of anaphylaxis or severe systemic reactions to zemaira or a1 -pi protein. - zemaira is contraindicated in immunoglobulin a (iga)-deficient patients with antibodies against iga, due to the risk of severe hypersensitivity [see warnings and precautions (5.2)] . risk summary no animal reproduction studies have been conducted with zemaira and its safety for use in human pregnancy has not been established in controlled clinical trials. since alpha1 -proteinase inhibitor is an endogenous human protein, it is considered unlikely that zemaira will cause harm to the fetus when given at recommended doses. however, zemaira should be given with caution to pregnant women. in the u.s. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary there is no information regarding the excretion of zemaira in human milk, the effect on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for zemaira and any potential adverse effects on the breastfed infant from zemaira or from the underlying maternal condition. safety and effectiveness in the pediatric population have not been established. the safety and efficacy of zemaira in the geriatric population have not been established due to an insufficient number of subjects.